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High-ﬂow oxygen therapy
through nasal cannula:
Prospective observational study
in  an intermediate care unit
Dear  Editor,
During  the  last  two  decades,  systems  for  supplying  heated
and  humidiﬁed  oxygen  at  high  ﬂow  via  nasal  cannula  have
been  developed  as  an  alternative  to  standard  oxygen  sup-
ply  systems.  High-ﬂow  oxygen  through  nasal  cannula  (HFNC)
devices  consists  of  an  air  and  oxygen  mixer,  connected  via  an
active  heated  humidiﬁer  to  a  nasal  cannula,  allowing  supply
Table  1  Baseline  characteristics  of  the  sample  (n  =  28).
n
Women  (%)  14  (50)
Median  age  (p25--p75)  82  (67--87)
Median  APACHE  II  score  (p25--p75)  16  (14--18)
Arterial  hypertension  (%)  12  (42)
Diabetes  mellitus  (%)  12  (42)
COPD  (%)  7  (25)
Ischemic  heart  disease  (%) 7  (25)
Smoker  (%) 5  (18)
Home  oxygen  therapy  (%) 5  (18)
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Transfer  to  ward  (%)  22  (79)
Transfer  to  ICU  (%)  4  (14)
Death  (%)  2  (7)
APACHE: acute physiology and chronic health evaluation; COPD:
chronic obstructive pulmonary disease; ICU: intensive care unit.
Table  2  Compared  clinical  and  laboratory  parameters
prior and  after  HFNC.
Parameter  Prior  to
HFNC
After
HFNC
p
Heart  rate  (bpm)  90.5  84  0.01
Respiratory  rate  (bpm)  30  22  <0.001
PaCO2 (mmHg)  41.5  40  0.78
PaCO2 in  COPD  47  46  0.31
O2 saturation  (%)  86.5  98  0.001
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tsof  a  FIO2 of  21--100%  (regardless  of  ﬂow  speed)  with  ﬂow
of  up  60  L/min.1
We  conducted  a  prospective  observational  study  at  th
Intermediate  Care  Unit  (IMC)  in  a  tertiary  hospital  fro
March  2014  to  January  2015.  We  included  patients  wit
persistence  of  acute  respiratory  failure  (deﬁned  as  oxyge
saturation  measured  by  pulse  oximetry  or  arterial  bloo
gas  less  than  95%)  from  any  etiology,  despite  oxygen  deli
ered  through  face  mask  with  an  estimated  FIO2 greate
than  50%.  Patients  did  not  require  endotracheal  intubatio
--  invasive  mechanical  ventilation  or  otherwise  had  a  do
not-intubate  (DNI)  order.  Patients  with  PaCO2 over  50  mmH
or  pH  lower  than  7.28  were  excluded.  HFNC  was  deli
ered  by  the  Optiﬂow® with  the  MR850  humidiﬁer  (Fisher  
Paykel,  Auckland,  New  Zealand).  The  initial  FIO2,  the  ﬂow  o
oxygen  and  subsequent  adjustments  (including  progressiv
withdrawal  of  HFNC  and  switching  to  conventional  therap
were  established  by  the  attending  physician  according  to  th
patient’s  condition.
Clinical  variables  (heart  rate,  respiratory  rate)  and  arte
rial  blood  gas  prior  to  the  start  of  HFNC  and  after  2  h  o
use  were  recorded.  The  perceived  sensation  of  dyspnea  wa
assessed  using  the  Borg  CR10  scale  (from  0  --  no  dyspnea  
to  10  -- maximum  dyspnea)  and  the  comfort  of  the  devic
was  evaluated  using  a  visual  analog  scale  (from  1  --  ve
uncomfortable  to  10  --  very  comfortable);  both  variable
were  collected  prior  to  HFNC  use  and  immediately  follow
ing  removal  of  the  device.  The  sample  had  a  non-norm
distribution,  so  non-parametric  tests  were  used  for  statist
cal  analysis.  Paired  t  test  and  the  Wilcoxon  signed  rank-te
were  utilized  for  statistical  comparisons.
Baseline  characteristics  of  the  sample  are  detailed  
Table  1.  The  main  etiology  of  respiratory  failure  was  hea
failure  (11),  respiratory  infection  (11),  asthma  (3)  an
miscellaneous  (3).  HFNC  was  initiated  at  a  mean  FIO2 o
0.77  (range  0.5--1.0)  and  a  ﬂow  rate  of  52.4  L/min  (rang
40--60  L/min).  Two  subjects  (7.1%)  died  in  the  IMC,  one  du
to  gastrointestinal  bleeding  and  another  due  to  metastat
lung  cancer;  4  subjects  (14.2%)  required  admission  to  th
intensive  care  unit,  3  of  them  requiring  mechanical  intub
tion;  22  subjects  (78.5%)  were  discharged  from  the  IMC  and
transferred  to  hospital  ward  with  conventional  oxygen  ther-
apy.  The  mean  length  of  stay  in  the  IMC  was  46.1  h.  HFNC
was  used  continuously  in  all  cases,  with  a  median  duration
of  HFNC  of  24  h  (range  3--240  h).  Analysis  of  clinical  and
laboratory  parameters  prior  and  after  HFNC  are  detailed  in
Table  2.
lepH 7.43  7.44  0.47
Dyspnea  8  3  <0.001
Comfort  3.5  8  0.001
HFNC: high ﬂow oxygen therapy through nasal cannula; PaCO2:
partial pressure of carbon dioxide; COPD: chronic obstructive
pulmonary disease.
In  adults,  the  use  of  HFNC  has  been  studied  in  mult
ple  situations.  In  patients  with  acute  respiratory  failure
a  study  showed  a  signiﬁcant  decrease  in  respiratory  rate
improvement  of  dyspnea  according  to  the  Borg  scale  an
increase  in  PaO2.2 The  same  group  obtained  similar  resul
in  patients  with  acute  respiratory  failure  despite  conven
tional  oxygen  therapy  in  an  intensive  care  service.3 A  clinic
trial  comparing  HFNC,  conventional  oxygen  therapy  an
noninvasive  mechanical  ventilation  demonstrated  a  redu
tion  in  mortality  at  30  days  in  patients  treated  with  HFN
against  other  modalities,  but  no  differences  were  found  
terms  of  the  need  for  progression  to  invasive  ventilation
Being  an  IMC  unit,  where  a  signiﬁcant  proportion  of  patien
have  DNI  order,  the  baseline  characteristics  of  our  samp
substantially  differ  with  studies  mentioned  above,  mainly
in  the  fact  that  our  population  is  older  and  they  present
with  greater  severity  at  admission.  In  most  of  our  patients,
the  etiology  of  respiratory  failure  were  heart  failure  and
respiratory  infection,  conditions  that  are  reversible  with
adequate  treatment,  which  allowed  progressive  withdrawal
of  HFNC  and  switching  to  conventional  oxygen  therapy  in
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edian  of  24  h.  Our  ﬁndings  support  the  use  of  respira-
y  therapy  HFNC  as  an  alternative  to  NIV  in  non-severe
percapnic  patients  for  whom  tracheal  intubation  is  not  an
tion.
In  the  analysis  of  the  subgroup  of  patients  with  a  prior
gnosis  of  COPD,  no  signiﬁcant  changes  in  pH  or  PaCO2
els  were  found.  However,  all  the  patients  in  our  sam-
 had  pH  >  7.28  and  PaCO2 <  50  mmHg.  Caution  should  be
en  in  severe  hypercapnic  patients  with  HFNC,  since
nical  evidence  for  the  use  of  HFNC  in  patients  with
ronic  CO2 retention  is  low  and  its  use  in  a  systematic
y  in  these  patients  is  not  recommended;  several  ongo-
 studies  are  trying  to  assess  the  use  of  HFNC  in  these
tients.5
Regarding  the  improvement  in  dyspnea,  other  studies
ve  found  similar  results  in  terms  of  comfort.1,6,7 A  clini-
l  trial  compared  HFNC  with  Venturi  mask,  showing  greater
mfort,  fewer  desaturations  and  interface  displacements
patients  with  HFNC.8
In  short,  HFNC  improves  oxygenation  in  patients  with
ute  hypoxemic  respiratory  failure  despite  conventional
 ﬂow  oxygen  therapy,  without  affecting  pH  or  PaCO2,
th  good  results  in  terms  of  comfort  and  reduction  of  dys-
ea.
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thma prevalence in
rtuguese preschool children:
e latest scientiﬁc evidence
ar  Editor,
thma  is  the  most  common  and  important  chronic  non-
children  is  scarce  and  has  not  been  compiled.  Therefore,
as  part  of  the  INAIRCHILD  project,2 this  letter  aimed  to
review  the  major  scientiﬁc  ﬁndings  of  the  most  recently  pub-
lished  papers  on  childhood  asthma  prevalence  in  Portuguese
preschool  aged  children.
Articles  published  from  2005  to  date  were  identiﬁed  in
the  following  on-line  databases:  Science  Direct, Scopus,
PubMed,  and  Google  Scholar.  Only  studies  in  press  or  fullyectious  disease  in  childhood  and  its  prevalence  has
reased  in  recent  years.1 However,  information  on  child-
od  asthma  prevalence  research  covering  Portuguese  young
pu
Alt
yeblished  (in  English  and/or  Portuguese)  were  analyzed.
hough  8  studies  were  found  published  in  the  last  10
ars  on  the  assessment  of  childhood  asthma  prevalence
